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Abstract Bovine spinal dysmyelination (BSD) is a reces-
sive congenital neurodegenerative disease in cattle (Bos
taurus) characterized by pathological changes of the myelin
sheaths in the spinal cord. The occurrence of BSD is a
longstanding problem in the American Brown Swiss (ABS)
breed and in several European cattle breeds upgraded with
ABS. Here, we show that the disease locus on bovine
chromosome 11 harbors the SPAST gene that, when
mutated, is responsible for the human disorder hereditary
spastic paraplegia (HSP). Initially, SPAST encoding Spastin
was considered a less likely candidate gene for BSD since
the modes of inheritance as well as the time of onset and
severity of symptoms differ widely between HSP and BSD.
However, sequence analysis of the bovine SPAST gene in
affected animals identified a R560Q substitution at a
position in the ATPase domain of the Spastin protein that
is invariant from insects to mammals. Interestingly, three
different mutations in human SPAST gene at the equivalent
position are known to cause HSP. To explore this
observation further, we genotyped more than 3,100 animals
of various cattle breeds and found that the glutamine allele
exclusively occurred in breeds upgraded with ABS.
Furthermore, all confirmed BSD carriers were heterozy-
gous, while all affected calves were homozygous for the
glutamine allele consistent with recessive transmission of
the underlying mutation and complete penetrance in the
homozygous state. Subsequent analysis of recombinant
Spastin in vitro showed that the R560Q substitution
severely impaired the ATPase activity, demonstrating a
causal relationship between the SPAST mutation and BSD.
Keywords Inbreeding.Hereditarydisease.Animalmodel.
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Introduction
Domestic animals provide a valuable resource for studying
the genetics of phenotypic variation in quantitative produc-
tion and health traits as well as for the identification of
mutations underpinning hereditary defects [1]. In cattle, the
emergence and spreading of genetic diseases caused by
inbreeding is a recurrent phenomenon, demonstrating that
international trading of semen from elite bulls and artificial
insemination accelerates dispersal of deleterious alleles
[2, 3]. An efficient mean to control genetic diseases is to
implement DNA-based testing for the causative mutation in
breeding programs in order to avoid at-risk matings. A
prominent example is the globally distributed complex
vertebral malformation syndrome in the Holstein Friesian
population, where the origin of the undesirable gene
mutation has been traced back to a specific founder animal
[4, 5]. Bovine spinal dysmyelination (BSD) is one of
several neurodegenerative disorders in cattle, and the
recessive mutation underlying BSD was widely spread in
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DOI 10.1007/s10048-009-0214-0Europe because American Brown Swiss carriers were used
to upgrade European cattle breeds such as the Danish Red
Dairy breed [6]. The main clinical signs of BSD are
manifested immediately at birth and include, most notably,
lateral recumbency with slight to moderate opisthotonos,
body tremor, and spastic extension of the limbs (Fig. 1a)
[7–9]. General muscle atrophy resulting from denervation
occurs to variable degrees and is most obvious in the hind
limbs. Attempts to rise and limb movements are absent;
however, the animals remain alert to their surroundings, and
spinal reflexes are normal or slightly increased. The
morphological cause of the phenotype is bilateral symmet-
rical hypo- and demyelination of axons in the cervical and
thoracic segments of the spinal cord. The lesions are
particularly prominent in the ascending gracile funiculus,
the ascending dorsal spinocerebellar tracts, and in the
descending sulcomarginal tracts (Fig. 1b)[ 8, 9]. Other
characteristic features are a reduced number of axons and
astrogliosis in the affected tracts. In contrast, the nerve cell
bodies in the gray matter of the spinal cord are unaffected,
and myelination defects are not observed in any other parts
of the nervous system.
We have previously mapped the BSD disease locus to a
narrow interval on bovine chromosome 11 [6], but strong
candidate genes were not identified in the unfinished, early
version of the bovine genome sequence. Recently, a new
assembly of the bovine genome sequence (Btau_4.0,
released October 2007) showed that the disease locus
contains the SPAST gene, which in its mutated form is
known to cause hereditary spastic paraplegia (HSP) in
humans. HSP is a disorder of the central nervous system
characterized by lower extremity weakness, spasticity, and
progressive gait disturbance. SPAST encodes a microtubule-
severing enzyme, and disease mutations are morphologi-
cally associated with progressive axonopathy of spinal
neurons. A priori SPAST seemed unlikely as a candidate
gene for BSD for two reasons. First, HSP associated with
mutations in SPAST is inherited as a dominant trait in
humans, which is different from the recessive mode of
inheritance of BSD in cattle. Second, affected calves
display very severe symptoms of spinal dysmyelination
immediately after birth, whereas the clinical features of
human HSP are mild initially and usually do not appear
before the second to fourth decade of life [10]. It was
therefore unexpected when our sequence analysis of SPAST
in affected animals identified a disease-causing mutation
that results in an arginine to glutamine change in the highly
conserved ATPase domain of Spastin.
Materials and methods
SNP genotyping
We applied the ABI Prism TaqMan Allelic Discrimination
Assay to type 3137 individuals for the G/A mutation in the
SPAST gene. The reactions were prepared by using TaqMan
Universal Master Mix, 30 ng of genomic DNA, and
custom-made primers and minor groove binder probes from
Applied Biosystems in a 10-µl reaction volume. The
polymerase chain reaction (PCR) amplification was per-
formed under the following conditions: 10 min 95°C
enzyme activation followed by 40 cycles at 95°C for 15 s
and 60°C for 1 min (annealing/extension). Allele discrim-
ination was accomplished by running end point detection
using the ABI Prism 7900 HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) and the
Sequence Detection System version 2.2 software.
GST-Spastin constructs, expression, and purification
First strand cDNA was synthesized from approximately 4
µg total RNA and 0.5µg oligo(dT)12-18 primer using the
Fig. 1 Clinical and pathological characteristics of bovine spinal
dysmyelination. a Phenotypic appearance of a calf affected with
bovine spinal dysmyelination. b Whole slide digital microscopic
image of cervical spinal cord stained with Luxol fast blue. Lack of
myelin is seen as reduced blue staining in the ascending gracile
funiculus (a), the ascending dorsolateral spinocerebellar tracts (b), and
the descending sulcomarginal tracts (c)
176 Neurogenetics (2010) 11:175–183superscript II RNase H-reverse transcriptase system (Invitro-
gen). A cDNA fragment encoding wild-type Spastin between
amino acid positions 227 and 614 was obtained by BamHI
digestion of a PCR product, which was generated using the
forward primer 5′CTGGGATCCGAAAGTGGAGCTGTTC
CAAAAAGA3′ and the reverse primer 5′GACGGATCCT
TACACAGTGGTATCTCCAAAGTCCT3′. PCR contained
1.5 mM MgCl2, 0.2 mM dNTP, 0.5 μM primer, and 0.2 U
Phusion DNA polymerase (Finnzymes) in a total volume of
10µL. The PCR fragment was cloned into the unique BamHI
site of the pGEX-6P-3 vector to generate an in-frame fusion
protein with glutathione S-transferase (GST). Site-directed
mutagenesis (QuickChange, Stratagene) using the comple-
mentary primers 5′GATGCAGCACTGGGTCCTATCCAA
GAACTGAAACCAGAACAAGTGA3′ and 5′TCAC
TTGTTCTGGTTTCAGTTCTTGGATAGGACCC
AGTGCTGCATC3′ was performed to generate a vector that
encodes a fusion protein between GST and mutated Spastin
harboring the R560Q substitution. Escherichia coli BL21
cells were transformed with wild-type and mutant GST-
Spastin fusion constructs. Protein expression was induced in
100 ml LB cultures at an OD600 of 0.8 by addition of
isopropyl-D-thioglucoside to a final concentration of 0.5 mM
for 4 h at 25°C. Cells were harvested by centrifugation and
incubated in 2 ml extraction buffer (140 mM NaCl; 10 mM
Na2HPO4; 1,8 mM KH2PO4;1m MA T P ;1m MD T T ;a n d
EDTA-free protease inhibitor; pH7.5) and 1 mg/ml lysozyme
for 15 min at 0°C. Cell extracts were prepared by sonication,
and GST-Spastin fusion proteins were affinity-purified using
glutathione-agarose beads according to manufacturer’s
instructions (Clontech). ATPase activities were measured
using an EnzChek Phosphate kit (Molecular Probes). The
ATPase assays were repeated three times.
Expression analysis
Total RNAwas extracted using the Quiagen RNeasy kit with
on column DNase digestion. From each tissue, 1.5µg total
RNA was reverse transcribed using an oligo dT primer and
Superscript II (Invitrogen) in 20µl as recommended by
supplier. Expression in different tissues was monitored by
PCRusing22cyclesinanattempttomeasure amplificationin
the exponential phase of the reaction. PCR products were
analyzed on 2% agarose gels stained with ethidium bromide.
DNA sequencing
DNA sequencing was performed using BigDye Terminator
v.3.1 Cycle Sequencing Kit (PE Applied Biosystems) accord-
ing to the recommendations of the manufacturer. The DNA
sequences were run on a 3730xl DNA Analyzer (PE Applied
Biosystems) and were analyzed using the Sequencher
software (version 4.0.5, Gene Codes Corporation).
Results
Candidate genes for BSD
The BSD locus was known from a previous mapping effort,
which showed that a 2.6-cM region between microsatellite
markers BP38 and BMS1953 on chromosome 11 cosegre-
gated with the disease [6]. The recent assembly of the draft
genome sequence of Bos taurus (http://www.ensembl.org;
assembly Btau_4.0; 7× sequence coverage) revealed the
presence of approximately 32 genes in the critical interval,
including the SPAST gene (Fig. 2a). The disease gene
responsible for spinal dysmyelination is presumably
expressed in the bovine central nervous system. Thus, as
a first evaluation of SPAST as a candidate for BSD, the
expression was investigated by reverse transcriptase PCR in
a selection of tissues (Fig. 2b). The data showed that the
SPAST gene was ubiquitously expressed including in the
neural tissues, cervical and lumbar spinal cord, cerebellum,
and frontal cortex. To further investigate the possible
association of SPAST with BSD, we analyzed the cDNA
sequence from a BSD carrier for the presence of mutations.
RNA was isolated from spinal cord tissue and reverse
transcribed into cDNA in order to be used for amplification
of cDNA encoding Spastin. Sequence analysis identified
three different splice variants. The longest SPAST cDNA
encoded 614 amino acid residues, which is highly similar to
the full length of Spastin in other species (Fig. 3). Spastin
belongs to the AAA protein family (ATPase associated with
various cellular activities), which is a group of Walker-type
ATPases. The conserved AAA module is located between
amino acid residues 327 and 601, and it contains several
functional domains essential for ATP binding and hydrolysis,
which are the Walker-homology motifs A and B between
positions 380–387 and 435–442, respectively, and an arginine
finger (496-RR-497) associated with the second region of
homology between residues 482 and 498. Phylogenetic
analysis of AAA proteins places Spastin in the “meiotic”
subgroup or subfamily 7 together with katanin, which is a
microtubule-severing protein like Spastin [11].
A potential disease-causing mutation in SPAST
In addition to the full-length cDNA, the sequencing
analysis also identified two smaller splice products of
which one variant lacked the nucleotides encoded by exon
4, and the other variant lacked two amino acid residues due
to alternative splicing of exon 12. Furthermore, two single
nucleotide polymorphisms were discovered: a silent poly-
morphism (A253A) and a missense polymorphism, which
replaces the amino acid residue arginine with glutamine at
position 560. Sequencing of the corresponding genomic
locus established that wild-type and affected calves were
Neurogenetics (2010) 11:175–183 177homozygous for arginine and glutamine, respectively,
whereas carriers were heterozygous (Fig. 4). The R560Q
substitution is remarkable for two reasons: First, arginine at
this position is completely conserved from insects to
mammals, indicating functional importance of this amino
acid (Fig. 2); second, several different amino acid sub-
stitutions at the equivalent position (the human protein is
two amino acid residues longer than the bovine protein) in
human Spastin are associated with disease. Thus, muta-
tional analysis of probands of unrelated HSP families has
detected two different disease-associated missense muta-
tions, R562Q [12] and R562G [13], and one nonsense
mutation, R562X [14].
Family and population-based genotyping
BSD is a recessive trait, and obligate carriers such as the
parents of affected calves must therefore be heterozygous for
the glutamine allele, while the calves with BSD must be
homozygous. To test this, we genotyped genomic sequences
encoding the R560Q variant in 33 calves, which have been
diagnosed as BSD affected on the basis of postmortem
neuropathological examination, as well as a group of 68
individuals comprising available parents and grandparents.
Some of these animals were previously used in the genome-
wide screen that led to the identification of the disease locus
on BTA11. All affected animals had the purebred American
Brown Swiss bull White Cloud Jason’s Elegant as a common
ancestor. The data showed that all obligate carriers were
heterozygous and that all affected calves were homozygous
for the glutamine residue. This result strengthens the
conclusion that the R560Q substitution is causative for the
disease (Fig. 3).
To test whether the Glu560 allele occurred generally in
bovine populations, we analyzed more than 3,100 animals
comprising six different cattle breeds for the presence of the
R562Qpolymorphism(Table1). The samples were randomly
selected from the national cattle DNA bank and without prior
knowledge of their carrier or disease status. The data showed
that the glutamine allele was unique for breeds cross-bred
with American Brown Swiss such as the Danish Red Dairy
breed and the Danish Red Holstein (Table 1). Moreover,
pedigree analysis showed that heterozygous animals for
which the pedigree information was available could be traced
back to confirmed BSD carriers. Furthermore, we identified
four animals, which were homozygous for the glutamine
residue; importantly, registration records showed that these
four calves were previously diagnosed as BSD affected
based on postmortem examination, and that they have
confirmed BSD carriers appearing on both the paternal and
maternal sides. We conclude that the glutamine allele
occurred exclusively in breeds and families in which the
disease segregates.
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Fig. 2 a Physical map of the bovine spinal dysmyelination locus
between the linked microsatellite markers BP38 and BMS1953. The
location and order of the genes are shown according to the cattle
genome assembly Btau_4.0. b Expression analysis by reverse
transcription-polymerase chain reaction of SPAST. Tissues analyzed
are SC1 spinal cord 1 (cervical), SC2 spinal cord 2 (lumbar), CE
cerebellum, FC frontal cortex, HE heart, MG mammary gland, and LI
liver
178 Neurogenetics (2010) 11:175–183B. taurus -MNSPGGRGKKKGSGGPSSPVP-----PRPPPPCQARSRPAPK---------PAPPPQSPHKRNLYYFSYPLFLGFALLR 65
H. sapiens -...............A.N...-----.......L.PAP..AG---------.....E...............V...... 65
X. laevis -.......ND..KPVT.AAETG--------.GSPTTPPSTETQ---------VVLA.P.......HL.....LAV.S... 62
G. gallus -.............A.S..AP.AAGAS.SA.SGPAPPAP..GA---------A.AAAA...............AA..... 70
D. rerio -...--.HKARLRG.RACG..S----------------------------------DG.ARGNR.LFYTRS.SR---VPE 40
A. mellifera MSY.D...PIR.YGTKSPKKLCVTKNENSDKTTTTINCNNHHHNHYHHNHRFLDA.QP.V......IV.F..I.L.NV.. 80
B. taurus LVAFHLGLLFVWLC----QRFSR-----------ALMAAKRSSGAAPA--SASPPAPVPGGEAERVRA------------ 116
H. sapiens ..............----.....-----------..............PA...A.............V------------ 118
X. laevis FL..Q.......C.----ELL..-----------SV..D.GRTV.S------TAA.QDRPQ.P.V..S------------ 109
G. gallus F...Q....VA...----E.L..G----------......S.R---------AGD..E...A......------------ 115
D. rerio WLLRV.L..LR..F----.PIR.------------A...RAKECG--------.DGSEET.--..I.N------------ 82
A. mellifera TLLYQ.FVV.KY.YTSTS.LIQ.RQACKQTCQLEIVVGQ.S.ENLNNN--LNNTEQIENE.MSQVP.RPIGPGPGDPLLA 158
B. taurus ----FHKQAFEYISVALRIDEDEKVGQKDQAVEWYKKGIEELEKGIAVVVTG-QGEQCERARRLQAKMMTNLVMAKDRLQ 191
H. sapiens ----..........I.........A...E...................I...-........................... 193
X. laevis ----Y.Q...Q...L...V..E..D-..E...Q...............PIS.-K...YD.........S...I....... 183
G. gallus ----C..R...C..M........RA...E..............R....L.V.-..D.........S......A....... 190
D. rerio ----Y......F.....Q......G-D.QK..Q..R...A......QIQ...-A..KAD...K..D..I...S..E...K 156
A. mellifera KQKHH.RR...F..K..K....NEG-..EM.I.L.....G.......IEC..GR..VW.H.Q..HD..R...A......D 237
B. taurus LLEKLQPSLQFSKSQTDVYND------STNLTCRNGHLQSE--SGAVPKR-KDPLTHASNSLPRSKTVMKTGPTGLSGHH 262
H. sapiens ....M..V.P...........------....A.........--.......-......T..............SA...... 264
X. laevis ..A...ADI.GPH..ME.CS.------N...P....L.KP.--K.....K-...PPIT...YS.T.APP.S.SL.----N 250
G. gallus ......AD..I..P.ME....------....A.........--......K-......T..........A...S....... 261
D. rerio ..GN.LS-----Q.PAESSS.------DSFYSFS..N.RPAPA....S.K-..T..ITNQTSL.P.NPP.S--------- 215
A. mellifera F.GLIRRNIHTLQTTRSSL.TNHTKNTNSTQ.VNI.QNTCTQIPKLR.RSP.NYSA.SEA.GRKLSVPG.RVG.VI.KSQ 317
B. taurus RAPSCSGLSMVSGVRQ------GPGSAAAT--HKSTPKTN-RTNKPSTPTTAA----RKKKDLKNFRNVDSNLANLIMNE 329
H. sapiens ....Y.........K.------.S.P.PT.--..G.....-...........T----....................... 331
X. laevis .I.N.T--.VPTSA..------AGAHTPSN--RGA.G.N.T.....A.....V----...-.M..L...........L.. 315
G. gallus .T..Y..I.TA.VS.P------AANP.TS.--..AA..NS-.........P..----.....T.V............L.. 328
D. rerio -T.NA...NCTPSAA.------SSRTGPQNNQKGP.V.GKNNVKAST.A.ASP----QR.R.M...K....K..S..L.. 284
A. mellifera TL.RSM.R.TAIQSCHRVAPIKPSSTPPSVKRQL.V.GNGSPIRR.G...ASNSNRGTPTRKVPILKG..PK..QV.LD. 397
B. taurus IVDNGTAVKFDDIAGQELAKQALQEIVILPSLRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAAESNATFFNISAASL 409
H. sapiens ................D............................................................... 411
X. laevis ...S.PS...A.....D..............I................................................ 395
G. gallus ...S.P.......................................................................... 408
D. rerio ...S.SV.R.......D.............A..................................M............T. 364
A. mellifera .LEG....HWE......T.......M...............T................L..R...TQC.....S...... 477
B. taurus TSKYVGEGEKLVRALFAVARELQPSIIFIDEVDSLLCERREGEHDASRRLKTEFLIEFDGVQSAGDDRVLVMGATNRPQE 489
H. sapiens ................................................................................ 491
X. laevis ................S..............................................G................ 475
G. gallus ...............................................................S.E..I........... 488
D. rerio ...............................I...............................G..E............. 444
A. mellifera ................SI.......V..........S...DN..E..........V....LPCNPEE.....A....... 557
B. taurus LDEAVLRRFTKRVYVSLPNEETRLLLLKNLLCKQGSPLTQKELAQLARMTNGYSGSDLTALAKDAALGPIRELKPEQVKN 569
H. sapiens .........I........................................D............................. 571
X. laevis ..D............A........V......S...N..SE...T..S.L.E......I...................... 555
G. gallus ..D.....................I......S..................D..........V.................. 568
D. rerio .........A..I..A..T.....K......S.HRN..S....S....L.D........S..................R. 524
A. mellifera ....A..........T..DLR..IM...R..A.HND...SE..NEM.VL.E........G.............N.D...E 637
B. taurus MSASEMRNIRLSDFTESLKKIKRSVSPQTLEAYIRWNKDFGDTTV- 614
H. sapiens .............................................- 616
X. laevis .A......MKY...LG......C...HS...S.....Q.......- 600
G. gallus .........K..............L....................- 613
D. rerio ...H...D..I...L....R..........DQ.V...REY....GV 570
A. mellifera LDLNSV...TMQ..RD...R.R.....AS.A..EK.SFEY..VSL- 682
Fig. 3 Multiple sequence alignment of Spastin homologues. Key
domains in Spastin are color marked: The AAA domain ATPase
associated with diverse cellular activities (yellow), MIT microtubule
interacting and trafficking domain (purple), Walker A and B motifs
(green), and arginine finger and second region of homology (blue).
The arginine residue at position 560 is evolutionary conserved from
mammals to insects (red)
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of Spastin
The C-terminal, approximately 285 amino acids of Spastin,
contains an AAA ATPase domain (Fig. 3). To determine
whether the R560Q substitution affects the ATPase activity,
we created recombinant fusion proteins between Spastin
and GST, which were expressed in E. coli and purified by
affinity chromatography (Fig. 5a). ATP hydrolysis was
measured spectrophotometrically using a coupled enzyme
assay [15]. We used Spastin lacking amino acids 1–227
because this shortened version has been shown to be more
stable and soluble than the full-length protein [16]. ATPase
activity of wild-type and mutated Spastin were measured as
a function of time using wild-type Spastin denatured by
boiling as a control (Fig. 5b). The data demonstrated that
the R560Q substitution essentially abolishes the ATPase
activity of Spastin, thereby establishing a causal relation-
ship between loss of catalytic activity and BSD.
Discussion
HSP is a human disorder of the central nervous system with
clinical features usually beginning in the second to fourth
decade of life, although first symptoms may appear already
in early childhood or as late as in the eighth or ninth
decade. In its pure form, the disorder is characterized by
lower extremity weakness and spasticity, progressive gait
disturbance, hyperreflexia, and loss of vibratory sense,
whereas the complicated forms have additional neurologi-
cal symptoms such as reduced vision, auditory impairment,
mental retardation, or dementia. A conspicuous neuropath-
ological feature of pure HSP is decreased staining of myelin
in histological sections and a distal-to-proximal degenera-
tion of axons of the neurons in the lateral and anterior
corticospinal tracts and the fasciculi gracilis as well as in
the spinocerebellar tracts in about 50% of all patients.
Peripheral nerves and dorsal root ganglia and posterior
roots are usually unaffected [17]. HSP is a genetically
heterogeneous disorder with 29 causative genes and loci
identified to date, consisting of dominant, recessive, and
X-linked forms. Mutations in SPAST are the most common
cause of autosomal dominant HSP [18].
The present study provides interesting new insight into
the behavior of SPAST mutations. Thus, both HSP and BSD
are associated with spasticity and weakness of the lower
limbs due to dysfunction of specific nerve fibers of the
spinal cord. However, in humans, the vast majority of the
SPAST mutations act dominantly, apparently contrasting
with the bovine mutation identified in this study, which is
clearly recessive [6, 19]. The sole recessive mutation
identified to date in humans is a S44L substitution, which
has been found in individuals with mild, late onset HSP
[20]. The phenotypic effect of dominant SPAST mutations
in a homozygous state has not been reported in humans.
Interestingly, however, compound heterozygosity for the
S44L mutation and an adult onset SPAST mutation, P361L
or D470V, is associated with a marked increase in severity
of clinical symptoms as well as a decrease in time of onset
to infancy or early childhood, which is significantly earlier
than for each mutation separately [21, 22].
The difference in modes of inheritance, time of onset,
and severity between BSD and HSP is intriguing. In
humans, a wide spectrum of DNA alterations that include
nonsense, frame-shifts, deletions, insertions, and missense
mutations in the SPAST gene result in the dominant form of
HSP, which suggest that loss-of-function or haploinsuffi-
A TC C T A T C C G G A G T GG GA
G TC C T A T C C G G A G T GG GA
R TC C T A T C C G G A G T GG GA
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Fig. 4 Sequence of the missense mutation causing the R560Q
substitution. The chromatograms show the sequence of a genomic
fragment spanning the putative disease-causing mutation. Wild-type
and affected individuals were homozygous for arginine and glutamine,
respectively, whereas individuals with bovine spinal dysmyelination
carrier status were heterozygous
Table 1 Distribution of R560Q alleles in different cattle breeds
Breed RR RQ QQ
Red Danish Dairy 1,361 39 4
Danish Red Holstein 255 1 0
Holstein Friesian 913 0 0
Hereford 379 0 0
Limousin 93 0 0
Grauvieh 93 0 0
Population-based samples from six different breeds were genotyped
for the presence of the disease-causing amino acid substitution.
Samples were selected randomly without prior knowledge of carrier
and disease status
180 Neurogenetics (2010) 11:175–183ciency is a primary pathogenic mechanism. Furthermore,
Spastin forms a hexameric complex with itself [16] and
interacts with other proteins such as the endosomal protein
CHMP1B [23], tubulin [16], and also atlastin [24], which is
another HSP disease gene product. This implies that certain
missense mutations that destroy the catalytic activity of
Spastin but do not affect the ability of Spastin to assemble
into protein complexes may act in a dominant-negative
manner by reducing the level of fully functional Spastin
complexes below a critical threshold. These mechanisms
are of likely relevance in the context of the highly variable
penetrance of human SPAST mutations, where the age of
onset, the severity of symptoms, and rate of disease
progression vary considerably both between and within
families. This contrasts strongly with the situation in cattle,
where all calves are invariably affected already at birth. It is
possible that a heterozygous R560Q animal eventually
would develop symptoms of the disease if allowed to live
out its entire life, but we have no veterinary records to
substantiate this. Thus, the natural life span of a cow is
about 25 years but usually does not exceed 5–7 years in
modern dairy farming.
The affected calves have been subject to detailed clinical
and histopathological examination [7–9], and the results
from these studies now gain additional value considering
that the number of neuropathological studies of human
patients with SPAST mutations is limited [17, 25]. Impor-
tantly, affected calves exhibit a much more severe disease
phenotype than human patients with HSP and also far
worse than observed in a loss-of-function mouse model,
which develops a late and mild motor defect [26]. The most
striking observations were the severe myelin lesions and
hypomyelination of the nerve fibers in both ascending and
descending tracts in the spinal cord. The oligodendrocytes
contained myelin debris in the cytoplasm and displayed
necrotic changes characterized by karyorrhexis and vacuo-
lation. Furthermore, ultrastructural examination revealed
the presence of slightly swollen axons with accumulations
of disoriented microtubules and intermediate filaments, and
also highly swollen axons filled with organelles, especially
mitochondria and lysosomal bodies. These findings are
similar to observations on the loss-of-function mouse
model, which also develops focal axonal swellings that
are surrounded by thin myelin sheaths, and in addition
contain an abnormal accumulation of organelles and
disorganized neurofilaments [26]. The phenotype was
proposed to arise from impairment of microtubule-
dependent transport of organelles and neurofilaments in
axons. Thus, Spastin has been shown to target and
disassemble microtubules in cells, and recombinant Spastin
severs purified microtubules in vitro and in permeabilized
cells [27, 28]. This shows that Spastin is implicated in
microtubule severing like the homologous katanin protein
and suggest that dysregulation of microtubule dynamics
may underlie pathogenesis. Interestingly, Spastin has been
shown to interact with the CHMP1B protein, which plays a
role in intracellular membrane traffic events [23], and
mechanisms for axonal transport and trafficking seem to be
a unifying theme for several genes associated with HSP
[18]. Thus, SPG7-deficient mice are affected by distal
axonopathy and have massive accumulation of organelles
and neurofilaments in the axons, which are clear evidences
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Fig. 5 a Coomassie blue stain of a sodium dodecyl sulfate-
polyacrylamide gel. Recombinant wild-type and mutant Spastin fused
to glutathione S-transferase (GST) were expressed in Escherichia coli
and purified by affinity chromatography using glutathione sepharose
columns. Lane 1, molecular size marker. Lane 2, wild-type GST-
Spastin fusion protein. Lane 3, mutant GST-Spastin protein. b ATPase
activity of wild-type and mutated Spastin were measured as a function
of time. ATP hydrolysis was measured spectrophotometrically using a
coupled enzyme assay. Wild-type Spastin denatured by boiling served
as a control
Neurogenetics (2010) 11:175–183 181of impaired transport [29]. Furthermore, the SPG10 (KIF5A)
gene encodes a neuronal kinesin heavy chain protein, which
drives anterograde axonal transport of membranous organ-
elles and other cargo [30]. SPG20, encoding spartin, binds
the transport vesicle adaptor protein Eps15, which indicates
a role in endocytosis and vesicle sorting [31].
The present work establishes a causal relationship
between a recessive SPAST mutation and BSD, which is
an important step towards development of a gene-based
diagnostic test to control spreading of the disease as well as
to establish BSD as an animal model of the corresponding
human neurological disease. Furthermore, the unanticipated
discovery that a condition of congenital axonopathy and
severe myelination defects can be caused by SPAST
mutations suggests that cases of congenital hypomyelina-
tion neuropathy in humans should be investigated for
mutations in SPAST.
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